Title: Pfizer Healthcare Ireland Virtual Advisory Board on ALK+ NSCLC
Time: Monday 7th December 2020, 6.30pm – 9.00pm
1830: Welcome, Objectives & Introductions
Part 1: Data Presentation & Discussion (50 Minutes)
1840: ALK 2L+ Mechanisms of resistance and therapeutic goals in ALK+ NSCLC: are we heading towards an individualized treatment approach?
1915: Lorlatinib Therapy Management Discussion
Part 2: Data Presentation & Discussion (70 Minutes)
1945: ALK 1L CROWN interim readout (ESMO presentation)
Preparation Date: November 2020
This event “Pfizer Healthcare Ireland Virtual Advisory Board on ALK+ NSCLC“ is being hosted by Combined Media on behalf of Pfizer Healthcare Ireland. The meeting will be recorded for the purposes of producing a Medical Writer’s report. Your name and email address is required for you to register and join the event. Once you provide your name and email address Combined Media will provide you with the webinar link so you can access the online event. Please see the Combined Media Privacy Notice for more details on how Combined Media manages your personal data. Your details will be retained and passed to Pfizer in order to confirm your attendance at the event.
Combined Media or Pfizer will never use your name or email address for any marketing purposes.
Please see the Pfizer EEA HCP Privacy Notice for information on how Pfizer manages your personal data .
As part of our ongoing commitment to physician education and patient care, Pfizer Healthcare Ireland (“Pfizer”), is pleased to invite you to attend the Virtual Event better identified in the electronic invitation you have just received (the “Virtual Event”). The objectives, purpose and content of the Virtual Event are explained in the electronic invitation and event agenda/programme.
By receiving this invitation from Pfizer for attendance at this Virtual Event, you agree – click here for more details